Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin

Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus

“…If only those completing the trial were considered, this probability rose to 70.5% (44±89%). Despite the differences in the study design and the dose of thalidomide, as revealed by the overlapping of 95% CIs, these rates might be considered statistically similar to those of Knop et al 3 on CDLE (400 mg/day, n = 60, complete responders (CRs) = 65%) and data from other trials regarding recurrent aphthous stomatitis 7 (100 mg/day, n = 73, CRs = 45%) and Jessner's lymphocytic in®ltration 18 (100 mg/day, n = 28, CRs = 74%). In all of these cases, disease resolution was achieved over a similar time interval.…”

Comparison of histopathologic–clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: Multicenter study of 46 cases

“…Because of the absence of strict relationship between their efficacy and the existence of photoinduction of the skin lesions, antimalarial drugs may be used as firstline therapy, even in the absence of photosensitivity, as we did for our 26 patients with JLIS or LET. Notably, thalidomide, the only treatment that has been evaluated in a randomized controlled trial in JLIS, 30 was given to only 10 of our patients and never as first-line therapy.…”

Thalidomide: dermatological indications, mechanisms of action and side-effects

“…In a randomized controlled trial, 28 patients were randomly assigned to receive thalidomide 100 mg daily or placebo over a period of 2 months and were then switched to the other treatment 67 . After the first period, 11 of 13 patients treated with thalidomide were in complete remission, and the other two patients did not respond.…”